Comparison of modified Celsior solution and M-kyoto solution for pancreas preservation in human islet isolation.
Since the successful demonstration of the Edmonton protocol, islet transplantation has advanced significantly on several fronts, including improved pancreas preservation systems. In this study, we evaluated two different types of organ preservation solutions for human islet isolation. Modified Celsior (Celsior solution with hydroxyethyl starch and nafamostat mesilate; HNC) solution and modified Kyoto (MK) solution were compared for pancreas preservation prior to islet isolation. Islet yield after purification was significantly higher in the MK group than in the HNC group (MK = 6186 ± 985 IE/g; HNC = 3091 ± 344 IE/g). The HNC group had a longer phase I period (digestion time), a higher volume of undigested tissue, and a higher percentage of embedded islets, suggesting that the solution may inhibit collagenase. However, there was no significant difference in ATP content in the pancreata or in the attainability of posttransplant normoglycemia in diabetic nude mice between the two groups, suggesting that the quality of islets was similar among the two groups. In conclusion, MK solution is better for pancreas preservation before islet isolation than HNC solution due to the higher percentage of islets that can be isolated from the donor pancreas. MK solution should be the solution of choice among the commercially available solutions for pancreatic islet isolation leading to transplantation.
Noguchi
Hirofumi
H
Baylor All Saints Medical Center, Baylor Research Institute, Fort Worth, TX, USA. hirofumn@baylorhealth.edu
Naziruddin
Bashoo
B
Onaca
Nicholas
N
Jackson
Andrew
A
Shimoda
Masayuki
M
Ikemoto
Tetsuya
T
Fujita
Yasutaka
Y
Kobayashi
Naoya
N
Levy
Marlon F
MF
Matsumoto
Shinichi
S
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001681:Biological Assay; D004187:Disaccharides / Q000494:pharmacology; D004573:Electrolytes / Q000494:pharmacology; D005260:Female; D005942:Gluconates / Q000494:pharmacology*; D005971:Glutamates / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology*; D006639:Histidine / Q000494:pharmacology; D006801:Humans; D007515:Islets of Langerhans / Q000187:drug effects*; D008297:Male; D008353:Mannitol / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D014199:Trehalose / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology
C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005942:Gluconates; D005971:Glutamates; D006023:Glycoproteins; D019188:Organ Preservation Solutions; D014361:Trypsin Inhibitors; D008353:Mannitol; D006639:Histidine; D000255:Adenosine Triphosphate; D014199:Trehalose; D005978:Glutathione; C028665:urinastatin; C030691:gluconic acid